Contrasting Evaxion A/S (NASDAQ:EVAX) and aTyr Pharma (NASDAQ:ATYR)

aTyr Pharma (NASDAQ:ATYR) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Profitability

This table compares aTyr Pharma and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
Evaxion A/S	N/A	-61.43%	-34.23%

Institutional & Insider Ownership

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 5.0% of aTyr Pharma shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for aTyr Pharma and Evaxion A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1	0	1	1	2.67
Evaxion A/S	1	0	5	0	2.67

Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 253.70%. Given Evaxion A/S’s higher probable upside, analysts plainly believe Evaxion A/S is more favorable than aTyr Pharma.

Risk and Volatility

aTyr Pharma has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.

Earnings & Valuation

This table compares aTyr Pharma and Evaxion A/S”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190,000.00	66.29	-$74.12 million	($0.62)	-0.21
Evaxion A/S	$7.49 million	3.75	-$7.71 million	($1.21)	-2.57

Evaxion A/S has higher revenue and earnings than aTyr Pharma. Evaxion A/S is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Evaxion A/S beats aTyr Pharma on 7 of the 13 factors compared between the two stocks.

About aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.